Vantage Health Receives License After NASA and Nanobeak Enter Into an Exclusive Five-Year Commercial License Agreement
January 07 2014 - 9:30AM
Marketwired
Vantage Health Receives License After NASA and Nanobeak Enter Into
an Exclusive Five-Year Commercial License Agreement
REDWOOD CITY, CA--(Marketwired - Jan 7, 2014) - Vantage Health
Inc., (OTCQB: VNTH) and its parent company Nanobeak Inc. today
announced that NASA and Nanobeak have entered into an exclusive
5-year license agreement to commercialize mobile healthcare
products derived from NASA patented chemical sensing technology.
This exclusive 5-year license agreement has been sublicensed to
Vantage Health Inc.
Telemedicine and mobile healthcare is formed by the intersection
of medicine and digital technology. Nanobeak and Vantage Health
have been developing sensor based mobile applications based on
patented NASA technology, for non-invasive disease screening at the
earliest stages, to be implemented for point of care and
individualized healthcare screening using a proprietary
breathalyzer attached to a smartphone.
The initial exclusive commercialization agreement with NASA
licenses the use of multiple US Patents relating to inventions in
the fields of nanotechnology, chemical sensing, carbon nanotubes,
medical diagnoses, environmental sensing and cell phone
applications. The commercialization agreement requires that the
products be manufactured substantially in the United States, and
are subject to certain annual royalty payments to NASA. We will use
this sensor technology to focus on certain forms of disease
screening and narcotics screening. The initial application will be
lung cancer.
The sensor technology won the 2012 NASA Government Invention of
the Year, which was announced on April 10, 2013. The sensors have
been deployed by NASA to detect trace gases in the crew cabin on
the International Space Station. Other federal agencies are using
sensors based on this technology to detect trace gases in various
environments. Specific applications for which the innovative
sensors have been tested and used include trace chemical detection
in planetary exploration, air monitoring, leak detection and
hazardous agent detection using cell phones.
Vantage Health is focused on early screening of lung cancer,
colon cancer, breast cancer, prostate cancer and ovarian cancer. We
are also developing mobile screening capabilities for medical
adherence, heart failure, diabetes, tuberculosis, oxidative stress
disorder, metabolic impairment, and HIV/Aids. Cancer is the number
two cause of death in America, second only to heart disease
according to the Center for Disease Control and Prevention. The
World Health Organization statistics indicate that 7.6 million
people die from cancer a year -- representing more than 20,000
deaths a day.
Commenting on today's announcement, Jeremy Barbera, Chairman and
CEO of Vantage Health, stated, "By analyzing a person's breath
print, the Vantage Health Sensor will provide low cost,
non-invasive lung cancer screening for the earliest stages when
there are more treatment options available for that person. There
were more deaths in 2012 from lung cancer than from prostate,
pancreas, breast and colon combined according to the American
Cancer Society. The primary reason is that only 15% of lung cancer
cases are screened at an early stage -- 85% are not."
"Our mission is to commercialize mobile healthcare technologies
that provide physicians and consumers with the tools to better
manage the healthcare continuum from managing illness to managing
wellness."
About Vantage Health Inc. Vantage Health Inc. -- a leader in
mobile health technology -- is developing personalized and
point-of-care screening using Apps based upon chemical sensing
residing within a small device attached to a smartphone.
With its foundations in advanced nanotechnology, the company's
first product, the Vantage Health Sensor, is the convergence of
nano-electronics, bio-informatics, and wireless technology to
create the next generation mobile health application.
The first mobile App is expected to be for lung cancer screening
with additional mobile healthcare Apps in the planning stages. The
company has offices in Redwood City, CA and New York. For more
information, please visit http://www.vantagehealthinc.com
This press release contains "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve risks and uncertainties that could cause
actual results to be materially different from historical results
or from any future results expressed or implied by such
forward-looking statements. Such forward-looking statements
include, among other things statements with respect to our
objectives and strategies to achieve those objectives, as well as
statements with respect to our beliefs, plans, expectations,
anticipations, estimates or intentions. Such forward-looking
statements may also include statements, among other things,
concerning the efficacy, safety and intended utilization of
Vantage's product candidates, the conduct and results of future
clinical trials, plans regarding regulatory filings, future
research and clinical trials and plans regarding partnering
activities. Factors that may cause actual results to differ
materially include, among others, the risk that product candidates
that appeared promising in early research and clinical trials do
not demonstrate safety and/or efficacy in larger-scale or later
clinical trials, trials may have difficulty enrolling, Vantage may
not obtain approval to market its product candidates, or outside
financing may not be available to meet capital requirements. These
forward-looking statements are based on our current expectations.
We caution that all forward-looking information is inherently
uncertain and actual results may differ materially from the
assumptions, estimates or expectations reflected or contained in
the forward-looking information, and that actual future performance
will be affected by a number of factors, including economic
conditions, technological change, regulatory change and competitive
factors, many of which are beyond our control. Therefore, future
events and results may vary significantly from what we currently
foresee.
For a further list and description of the risks and
uncertainties the Company faces, please refer to the Company's most
recent Annual Report on Form 10-K and other periodic and other
filings Vantage files with the Securities and Exchange Commission
and are available at www.sec.gov. Such forward-looking statements
are current only as of the date they are made, and Vantage assumes
no obligation to update any forward-looking statements, whether as
a result of new information, future events or otherwise.
Nano Mobile Healthcare (PK) (USOTC:VNTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nano Mobile Healthcare (PK) (USOTC:VNTH)
Historical Stock Chart
From Jul 2023 to Jul 2024